

## ASM News

### Sanofi-Aventis Pharmaceuticals Award



Craig

**William A. Craig**, Professor of Medicine, University of Wisconsin Medical School, and Professor of Pharmaceutics, University of Wisconsin School of Pharmacy, Madison, will receive the 2004 Sanofi-Aventis Pharmaceuticals Award. Supported by an unrestricted educational

grant from Sanofi-Aventis Pharmaceuticals, Inc., the Award recognizes outstanding accomplishments in antimicrobial chemotherapy. This year's presentation honors Craig for a distinguished career in applying pharmacological principles to antimicrobial therapy, achievements that are profoundly shaping the practice of infectious disease medicine.

Widely considered the founder of the field of pharmacodynamics for his studies of the complex relationships between the infecting pathogen and the antimicrobial agent, Craig is also known for a host of important findings on antimicrobial pharmacology. These include his studies of the postantibiotic effect (PAE), a period of persistent growth suppression of bacteria in vitro that persists even after the antibiotic agent is no longer present. He also demonstrated that increasing the levels of a drug may not increase the rate of bactericidal activity. Such findings are of crucial importance for clinicians treating drug-resistant organisms, who must decide how to structure dosing regimens for different classes of antibiotics.

The influence of Craig's work has been widespread, in both industry and clinical medicine. Many pharmaceutical companies now select dosages for clinical trials based on the pharmacodynamic requirements Craig has demonstrated from animal models. His pharmacodynamic data are also used extensively to develop practice and treatment guidelines, and his find-

ings have supported innovative dosage regimens, such as one-daily aminoglycoside dosage and continuous infusions of beta-lactams. As American Academy of Microbiology Fellow Robert C. Moellering, Jr., wrote in nominating Craig for the award, "I am unaware of any other person worldwide who has had a greater impact on the pharmacotherapy of bacterial infection."

After earning an A.B. degree from Haverford College, Haverford, Pa., Craig received his medical degree from Tufts University School of Medicine, Boston, Mass., and completed a residency in internal medicine and a fellowship in infectious diseases at the University of Wisconsin-Madison. After military service as a preventive medicine officer with the U.S. Army, he joined the medical school faculty of the University of Wisconsin.

A Fellow of the American Academy of Microbiology, Craig is also a Fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards for excellence as an educator as well as a clinician and researcher.

An active member of ASM, Craig has also devoted himself to ICAAC programming, with extensive commitments to the ICAAC Program Committee as committee member, vice chair, and chair. His editorial service includes his current position as an editor of ASM's *Antimicrobial Agents and Chemotherapy*.

The Sanofi-Aventis Pharmaceuticals Award includes a \$20,000 honorarium and a commemorative medal. At the upcoming 44th Interscience Conference on Antimicrobial Agency and Chemotherapy (ICAAC) in Washington, D.C., Craig will deliver the annual Sanofi-Aventis Pharmaceuticals Award Lecture.

### 2004 ICAAC Young Investigator Awards

The ICAAC Young Investigator Awards recognize and reward early-career scientists for re-

search excellence and potential in microbiology and infectious diseases. Since 1983, two Awards have been supported by an unrestricted educational grant from Merck, U.S. Human Health Division, while two are sponsored by ASM. **Eleftherios Mylonakis** and **C. Erec Stebbins** are the 2004 laureates for the Merck-sponsored awards, and **Mary C. Jackson** and **Kevin B. Laupland** are the 2004 laureates for the ASM-sponsored awards.



Mylonakis

Mylonakis is recognized for his work on the mechanisms of fungal pathogenesis, focusing on his development of a number of non-mammalian host models to study the human pathogenic fungus *Cryptococcus neoformans*. Mylonakis has received wide acclaim for the originality of his research. His doctoral work on the efficacy of various antifungal agents in rabbit models of *Aspergillus* endocarditis garnered him the First Amphiarion Prize in Chemotherapy Research at the 19th National Medical Conference in Athens, Greece, and he collaborated in research that won an Associates Research Award based upon presentation at the American College of Physicians 74th Annual Session.

Mylonakis is currently an Instructor in Medicine at Harvard Medical School in Boston, Mass., and Clinical Assistant in Medicine, Massachusetts General Hospital, Boston. He received both Medical and Doctoral degrees from National and Kapodistrian University in Athens, Greece. Mylonakis was nominated for the Award by Academy Fellow Stephen B. Calderwood.

**C. Erec Stebbins, Ph.D.**, Assistant Professor and Head of the Laboratory of Structural Microbiology at Rockefeller University, New York, N.Y., has been awarded the ICAAC Young Investigator Award for his interest and unique approach to pathogenesis. Stebbins is honored for his work in biochemistry and struc-

## Guidance Issued for General Meeting Abstract Peer Review

In an effort to maintain the high quality of presentations at the 2005 General Meeting, the General Meeting Program Committee has issued guidance to the Division Chairs to be more comprehensive in their peer review of 2005 abstract submissions, which ASM will begin receiving starting 15 October 2004. Authors planning to submit abstracts for review should keep in mind the following guidelines to ensure abstract acceptability:

- Make sure the abstract has a clearly defined hypothesis and conclusion.
- Adequately describe experimental methodologies used.
- Include sufficient data to support conclusions.
- Concisely summarize the essential results of the research.
- Check to make sure additional authors are not submitting abstracts on the same research. Duplicate abstracts will be rejected.
- Submit only research that is appropriate for the subject matter of the General Meeting.
- If it is not relevant to any ASM Division it will not be accepted.
- Abstracts that are promotional in nature (written to promote a specific product or procedure on behalf of a specific company or organization) will be rejected.
- Submitters for whom English is not their first language may wish to have a second party review their abstracts before submission. Improper use of the English language can render an abstract incomprehensible and therefore unacceptable.
- You may be the presenting author on only one abstract.

Deadlines for submission differ depending on the divisional group to which the abstract is designated, but all are in December 2004. For the exact deadlines please refer to the General Meeting Call for Abstracts on the ASM website at [www.asm.org](http://www.asm.org).

tural biology that has made significant contributions to our knowledge of the key virulence factors of some of the most dangerous pathogens. Stebbins is hailed as a “highly talented and innovative investigator,” according to Vincent A. Fischetti, an Academy Fellow who nominated Stebbins for the Award.

Part of his research has focused on the type III secretion system, a mechanism used by many bacterial pathogens to inject virulence proteins



Stebbins

into host cells. These virulence proteins then modulate host cell functions for the pathogen's benefit. In an important article published in the journal *Science*, Stebbins demonstrated how *Salmonella* invasion protein A (SipA) binds host actin, a filamentous protein, and functions as a "molecular staple" to stabilize filaments by tethering actin subunits in opposing strands.

In recent work published in the journal *Nature*, his group has determined the high-resolution structure of the cytolethal distending toxin, a DNA lesion-inducing genotoxin that is present in a wide range of gram-negative pathogens.

Stebbins received a B.A. in Physics from Oberlin College, Oberlin, Ohio, and his Ph.D. in Biochemistry and Structural Biology from the Joan and Sanford I. Weill Graduate School of Medical Sciences at Cornell University in New York, N.Y. Stebbins has been honored for achievements that include most recently the Molecular Structure Corporation Future Investigator Award and the Julian R. Rachele Prize, presented at Weill Graduate School of Medical Sciences.

**Kevin B. Laupland, M.D., M.Sc., FRCPC**, is presented the 2004 ICAAC Young Investigator Award for his work in clinical epidemiology, a population-based surveillance of antimicrobial resistance and infectious disease in the intensive care unit.



Laupland

Laupland's research focuses primarily on the incidence of gram-positive infections, particularly those caused by *Staphylococcus aureus*, and septic shock. He first received acclaim for his graduate work, the first population-based study to quantify the risk factors associated with invasive *S. aureus* infections. His research characterized populations at greatest risk for serious, sometimes fatal, infections and indicated the increases in risk for specific subgroups.

Laupland continues to study the phenomenon of invasive *S. aureus* infection; his most recent research was a widely cited article in the *Journal of Infectious Diseases*. This report of an active-surveillance study of the Calgary Health Region in Canada identified special groups at particular risk and presented important data on

the burden of illness from invasive *S. aureus* infection.

Laupland earned his Doctor of Medicine degree from the University of Toronto and went on to receive his Master of Science in Epidemiology degree at the University of Calgary. Currently, Laupland is Assistant Professor for the Departments of Medicine, Critical Care Medicine, and Pathology and Laboratory Medicine at the University of Calgary, as well as Deputy Director for the Centre for Antimicrobial Resistance.

Laupland was nominated by John M. Conly, Professor and Head of the Department of Medicine at the University of Calgary.

**Mary C. Jackson, Ph.D.**, Assistant Professor at the Institut Pasteur in Paris, France, receives the 2004 ICAAC Young Investigator Award for her substantial accomplishments in development of genetic tools for studying *Mycobacterium tuberculosis* and characterization of essential enzymes of this bacterium as therapeutic targets for novel antituberculosis drugs. According to Patrick J. Brennan, a Fellow of the American Academy of Microbiology who wrote in support of Jackson's nomination, Jackson has "extraordinary fundamental and practical knowledge of microbial genetics and biochemical principles."



Jackson

Jackson is recognized for her substantial accomplishments in developing genetic tools for studying the pathogen *Mycobacterium tuberculosis* and characterizing essential enzymes of this bacterium as possible therapeutic targets for novel antibiotic treatment. She contributed to the development of efficient insertional mutagenesis tools for mycobacteria, which were used to construct attenuated mutants of *M. tuberculosis* as new live vaccine candidates and to study virulence factors of the mycobacterial cell envelope.


Her approaches integrate the tools of functional and structural genomics, biochemistry, bioinformatics, proteomics, and immunology to pinpoint species-specific diagnostic antigens, identify novel drug targets, and screen for inhibitors. Other current research projects includes

the study of ATP-binding cassette transporters in the pathogenicity of *M. tuberculosis* and the role these transporters play in the bacterium's resistance to drugs.

Jackson received a bioindustrial engineering degree and an M.S. in Biology and Agronomy from the National School of Agronomy, Rennes, France. She earned a Ph.D. in Biochemistry and Molecular and Cellular Biology jointly from the National School of Agronomy and the Institut Pasteur. Jackson was nominated for the ICAAC Young Investigator Award by Stewart C. Cole of the Institut Pasteur in Paris.

## New Additions to Membership Board

Toby K. Eisenstein, chair, ASM Membership Board, is pleased to announce two new additions to the Board. **Paul Phibbs** has agreed to replace retiring Dixie Whitt as chair of the Membership Committee and **Amy Cheng Vollmer** has accepted the position of chair, Student Membership Committee, replacing outgoing Larry Hanne.



Phibbs

Paul Phibbs has a long association with the Membership Board, having served on the Underrepresented Minorities Committee, as an ASM Branch Regional Planning Coordinator for Region IV, and on the Council Policy Committee as an at-large representative of Branches. He has recently begun phased retirement from East Carolina University School of Medicine, where he was Professor and Chairman of Microbiology and Immunology and director of the School of Medicine Biotechnology Program. Phibbs stated that it is crucial the Membership Committee “develop new and aggressive campaigns to jump the wave of interdisciplinary science.”

Amy Cheng Vollmer has been active with student interests for over 10 years, both with ASM and independently. She has previously served on the Undergraduate Education Committee of the Education Board, and currently sits

on the Academy's ASM Founders Award Nominating Committee. Recognizing the importance of providing a support system for student microbiologists, Vollmer has expressed a desire to focus on career development, mentoring and other student needs. She intends to strengthen the Student Chapter system by encouraging “unique and creative ways to utilize the funding provided by ASM Branches to create meaningful activities.” Vollmer is currently the chair of the Biology Department at Swarthmore College.



Vollmer

## New Directions for Minority Education

The Committee on Minority Education met 16–18 July in Washington, D.C., to reaffirm its strategic plan and identify major initiatives for the next 3 to 5 years. The Committee's mission is to (i) promote access, excellence, and advancement in microbiology education, (ii) enhance the community of underrepresented microbiology educators and professionals, (iii) develop and promote educational leadership in the profession and at ASM, and (iv) promote full participation of underrepresented groups in the scientific enterprise of microbiology. The Committee envisions a more diverse workforce and a significant increase in the number of students pursuing studies and careers in microbiology.

**Student Programs.** The Committee recommended a number of changes to the student research program. First, the titles of the two minority fellowships have changed to the Robert D. Watkins Graduate Research Fellowship Program and the ASM Microbiology Undergraduate Research Fellowship (MURF) Program. In both cases, the word “minority” has been dropped from the titles. In addition, both programs have expanded their scope, offering opportunities to all underrepresented groups in the microbiological sciences. To expand this program, the Committee plans to leverage ASM funds. For example, the Society is currently working with the NIH Minority Supplement Program to support graduate students in microbiology. “In the proposed collaboration, the ASM will identify highly

## Call for ASM Research Fellows

The Committee is currently studying the influence of ASM's research fellowship program on students' personal and professional development. If you received an ASM fellowship, please send an email to [Fellowships-CareerInformation@asmusa.org](mailto:Fellowships-CareerInformation@asmusa.org) and put in the message line "ASM Fellow:your name." Include in the message your name and contact information, year of fellowship award, current position, and a short description of your career pathway. If you wish, attach your curriculum vitae. If you are a faculty mentor and know about previous fellows, please send an e-mail to ASM with pertinent information. The Committee's goal is to identify 100% of the ASM fellows by April 2005.

qualified applicants from the Watkins Program and recommend them for the NIH Minority Supplement Program. If successful, these students will receive support from NIH for their research," explains Anthony Madu, cochair of the Committee and a faculty member at Virginia Union University in Richmond.

The Committee will continue to support the Annual Biomedical Research Conference for Minority Students (ABRCMS), which each year brings together approximately 2,600 faculty and minority students to exchange scientific knowledge and highlight their accomplishments through oral and poster presentations. Specifically, the Committee will review and select the best abstracts, judge all the student presenters in microbiology, mentor students about graduate opportunities, and recruit them into the profession.

**Faculty Programs.** In 1995, the Committee established the Faculty Enhancement Program (FEP) to support biology faculty who teach microbiology courses at 2- and 4-year institutions with significant numbers of underrepresented students but who were not members of ASM.

"The FEP grantees received funds to attend the ASM Conference for Undergraduate Educators (formerly the ASM Undergraduate Microbiology Education Conference) and a one-year complimentary membership to ASM. Each year the Conference brings together faculty members to share their best teaching methods, discuss their teaching challenges, and keep abreast of the microbiological sciences," states Rosa del C. Torres of University of Puerto Rico, Cayey, who is cochair of the Committee. Since the FEP began in 1995, 34 biology faculty members have

been named FEP grantees and more than 60% have retained their ASM membership.

Visit <http://www.asm.org/Education/index.asp?bid=1185> for ASM student programs, [www.abrcms.org](http://www.abrcms.org) for the Annual Biomedical Research Conference for Minority Students, [www.asmcue.org](http://www.asmcue.org) for the Faculty Enhancement Program and ASM Conference for Undergraduate Educators, and [www.asm.org](http://www.asm.org) for all other information.

## ASM Corporate Activities Program

The ASM Corporate Activities Program is comprised of leaders in the scientific and pharmaceutical industries. They are ASM's most valued colleagues in the advancement of the Society's mission to support education and public information programs. CAP funds sustain the Student Scientist Program, which provides travel grants for students or postdoctoral fellows to present abstracts at either the General Meeting or ICAAC. Many CAP members also contribute to ASM's meetings, conferences, programs, and awards through individual grants and sponsorships.

The CAP logo (the ASM microscope and the year of CAP participation) identifies CAP corporations in various ASM publications. At the upcoming ICAAC, you may spot the logo on CAP lapel pins worn by ASM's principal corporate colleagues. ASM members and colleagues are encouraged to visit the CAP participants' web pages or booths at ICAAC exhibits to learn more about the companies that generously support ASM and its educational goals.



### 2004 Corporate Activities Program Members

There are two levels of participation: Corporate Partner, the higher level, and Corporate Sponsor.

**Corporate Partners** (as of 15 August 2004)

**Abbott Laboratories**  
6008 30th Avenue NE

Seattle, WA 98115  
www.abbott.com

Founded in 1888, Abbott Laboratories is a diversified health care company that discovers, develops, manufactures, and markets innovative products and services that span the continuum of care—from prevention and diagnosis to treatment and cure. Building leadership and combining strengths in the areas of pharmaceuticals, nutritionals, hospital products, and diagnostics has enabled Abbott to provide total, integrated solutions across the health care spectrum for some of the world's most prevalent medical conditions, including AIDS, cancer, and diabetes. Abbott's focus is on advancing medical science and the practice of health care with expertise in the therapeutic areas of diabetes, pain management, respiratory infections, HIV/AIDS, men's and women's health, pediatrics, and animal health. (Abbott Laboratories is exhibiting in ICAAC booths 532 and 537 and is conducting a satellite symposium on Saturday, 30 October at 7:30 PM entitled "Antibiotic Resistance in Adult Respiratory Tract Infections: Maximizing Current and Future Outcomes.")

#### **BD Diagnostic**

7 Loveton Circle  
Sparks, MD 21512  
www.bd.com/ds

BD Diagnostic serves clinical, industrial, research, and physician office laboratories around the world with solutions for disease diagnosis, blood banking, and physician office laboratory testing. BD is the market leader in microbiology with innovative new products in areas such as molecular diagnostics, tuberculosis testing, and microbial identification. BD offers products ranging from culture media to DNA probe assays used in clinical and physician office laboratories, biopharmaceutical fermentation media used in industrial settings, and many more products that enhance diagnostic and industrial processes. BD is dedicated to achieving cost-effective solutions by providing real-time diagnostic testing in hospitals and physician offices. (BD Diagnostic is exhibiting in ICAAC booth 1423.)

**Bristol-Myers Squibb Company**  
777 Scudders Mill Road

Plainsboro, NJ 08536  
www.bms.com

Bristol-Myers Squibb is a leading diversified worldwide health and personal care company whose principal businesses are medicines, beauty care, nutritionals, and medical devices. Bristol-Myers Squibb's mission is to extend and enhance human life by providing the highest-quality health and personal care products. (Bristol-Myers Squibb Company is exhibiting in ICAAC booths 622 and 1019 and is conducting a satellite symposium on Sunday, 31 October at 6:00 PM entitled "Making the Switch: Choosing First and Subsequent Regimens." Bristol-Myers Squibb is the sponsor of the ICAAC meeting portfolios.)

#### **Elan Pharmaceuticals, Incorporated**

7475 Lusk Boulevard  
San Diego, CA 92121  
www.elan.com

Elan Corporation is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing, and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan provides innovative drug optimization technologies, advanced manufacturing capabilities, and global supply chain management services. Elan's focus is on improving the health of patients suffering from chronic and debilitating conditions. (Elan Corporation is exhibiting in ICAAC booth 1237.)

#### **Gilead Sciences, Incorporated**

333 Lakeside Drive  
Foster City, CA 94404  
www.gilead.com

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has six commercially available products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, Calif., Gilead has operations in the United States, Europe, and Australia. (Gilead Sciences is exhibiting in ICAAC booth 827 and is conducting a satellite symposium on Sunday, 31 October at 7:00 PM entitled "HIV Hardball:

an In-Depth Analysis and Fiery Debate on Selecting the Best Regimens for the Treatment of HIV.”)

#### **GlaxoSmithKline Pharmaceuticals**

1250 South Collegeville Road  
Mail Code UP 13440  
Collegeville, PA 19426  
<http://corp.gsk.com>

GlaxoSmithKline (GSK) is a world-leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing health care environment. GSK's mission is to improve the quality of human life by enabling people to do more, feel better, and live longer. Headquartered in the United Kingdom and with operations based in the United States, the new company is one of the industry leaders, with an estimated 7% of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory, and gastrointestinal/metabolic. In addition, GSK is a leader in the important area of vaccines and has a growing portfolio of oncology products. (GlaxoSmithKline Pharmaceuticals is exhibiting in ICAAC booth 500 and is conducting a satellite symposium on Sunday, 31 October at 7:30 PM entitled “New Treatment Options for Living with HIV.” GSK is the sponsor for E-Central.)

#### **Ortho Biotech**

700 Route 202  
Raritan, NJ 08869  
[www.orthobiotech.com](http://www.orthobiotech.com)

Ortho Biotech Products, L.P. is in the business of helping seriously ill people get better and feel stronger with products that may help extend and enhance people's lives. Ortho Biotech markets prescription medications for correcting the anemias associated with cancer chemotherapy for patients with nonmyeloid malignancies; AZT-treated, HIV-infected patients; chronic kidney disease patients not on dialysis; and elective, noncardiac, nonvascular surgery patients. They also provide treatments for organ transplant rejection, a rare form of leukemia, cancer pain, and life-threatening fungal infections. The

company continually seeks new ways of meeting the needs of the health care community through new products and technologies and new programs that help doctors, nurses, patients, caregivers, patient advocates, and other health care professionals derive greater benefit from what they have to offer. Ortho Biotech is proud of their accomplishments and the many lives that have been made better and takes great pride in the fact that those who have been helped feel the same way. (Ortho Biotech is exhibiting in ICAAC booth 1232 and is the sponsor for the pocket programs.)

#### **Pfizer Inc**

235 East 42nd Street  
New York, NY 10017  
[www.pfizer.com](http://www.pfizer.com)

Pfizer Inc is a research-based, global pharmaceutical company. They discover and develop innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health, and consumer health care. Pfizer products are available in more than 150 countries. (Pfizer Inc is exhibiting in ICAAC booth 1417 and is conducting two satellite symposia, one on Sunday, 31 October at 7:30 AM entitled “Evolving Strategies for the Management of Invasive Fungal Infections,” and one on Saturday, 30 October at 7:00 AM entitled “Methicillin-Resistant *Staphylococcus aureus*: a Pathogen in Evolution.” Pfizer is the sponsor of the telephone calling cards.)

#### **Wyeth**

150 North Radnor Chester Road, A-2  
St. Davids, PA 19087  
[www.wyeth.com](http://www.wyeth.com)

Wyeth is committed to helping people throughout the world lead healthier lives through advances in health care. They are proud of the vaccines, medications, and nutritional products that are researched and developed and on quality manufacturing; responsible sales, marketing, and licensing alliances; commitment to educational programs and initiatives; and service to health care professionals and patients. (Wyeth is exhibiting in ICAAC booth 1400 and is

conducting a satellite symposium on Friday, 29 October at 6:00 PM, entitled "Optimizing Hospital Outcomes in an Era of Multiresistant Pathogens: a Global Perspective.")

### Corporate Sponsors

#### **Aventis Pasteur**

Discovery Drive  
Swiftwater, PA 18370  
www.aventispasteur.com

Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2002, Aventis generated sales of €17.6 billion, invested €3.1 billion in research and development and employed approximately 71,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. Aventis Pasteur, the vaccines business of Aventis, produced 1.4 billion doses of vaccines in 2002, making it possible to protect over 500 million people around the globe, which is about 1.4 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. (Aventis Pasteur is exhibiting in ICAAC booth 1432 and is conducting a satellite symposium on Saturday, 30 October at 7:30 AM entitled "Update on Preventive Strategies for Meningococcal Disease.")

#### **bioMérieux, Incorporated**

100 Roldophe Avenue  
Durham, NC 27712  
www.biomerieux-usa.com

bioMérieux is a major in vitro diagnostics company focusing on infectious diseases and develops, manufactures, and markets reagents and automated systems designed for medical analyses and product quality control in the agri-food, cosmetics, and pharmaceutical industries, and the environment. Their mission is to maintain a front-line position in the worldwide struggle against infectious diseases in clinical and industrial biology. To achieve this, they have developed a strategy that involves innovations in microbiology, immunoassays, and molecular diagnostics, strengthening their worldwide network and improving their operational profitability to free the resources needed to finance research and international development.

#### **Boehringer Ingelheim Pharmaceuticals,**

**Incorporated**  
900 Ridgebury Road  
Ridgefield, CT 06877  
www.viramune.com

Scientific excellence is one of Boehringer Ingelheim Pharmaceuticals' greatest strengths, and its principal mission is harnessing its human and technological resources to make significant improvements in human health. The company's clinical research organization is shepherding promising new medications for stroke, hypertension, arthritis, HIV, and pulmonary disease through clinical testing and regulatory review. In fact, Boehringer Ingelheim Pharmaceuticals anticipates the launch of 15 new products in the U.S. within the next five years, with many more candidates being added to the pipeline. Scientists at the company's state-of-the-art Research & Development facilities in Ridgefield, Conn., are focusing on the discovery and development of new medications that, through the mediation of the body's immunological and inflammatory processes, hold promise for the treatment of cancer, cardiovascular, respiratory, and autoimmune diseases, and central nervous system disorders. (Boehringer Ingelheim Pharmaceuticals is exhibiting in ICAAC booths 509 and 521 and is conducting a satellite symposium on Saturday, 30 October at 7:30 PM entitled "Tricks for the Hard Treat.")

#### **Cubist Pharmaceuticals, Incorporated**

65 Hayden Avenue  
Lexington, MA 02421  
www.cubist.com

Cubist engineers major advances against serious infections through a rigorous fusion of the most productive science and business technologies. By applying this unique model and focus, Cubist is dedicated to becoming a global leader in the development and commercialization of novel anti-infectives. (Cubist Pharmaceuticals is exhibiting in ICAAC booths 819 and 1149 and is conducting a satellite symposium on Saturday, 30 October at 6:30 PM entitled "Issues with Glycopeptides in the Treatment of Serious Gram-Positive Infections." Cubist is the sponsor for the City Maps.)

#### **Fujisawa Pharmaceutical Company, Limited**

2-1-6 Kashima  
Yodogawa-Ku

Osaka, 532-8514 Japan  
www.fujisawa.co.jp/english

Fujisawa's corporate philosophy is "Challenging the unknown frontier known as humans and contributing to healthier, more prosperous lives for people around the world." Fujisawa's commitment to R&D is central to the company's mission to provide new, innovative products that contribute to the health and welfare of people all over the world. Fujisawa leads the Japanese pharmaceutical industry in the development of international operations. Through its overseas subsidiaries and licensing agreements, the company is able to offer a broad range of pharmaceutical products worldwide. (Fujisawa is exhibiting in ICAAC booth 527 and is conducting a satellite symposium on Saturday, 30 October at 6:50 AM entitled "New Options in Systemic Antifungal Therapy.")

**Merck & Co., Incorporated**  
351 N. Sumneytown Pk.  
North Wales, PA 19454-2505  
www.merck.com

Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures, and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck's mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life and satisfy customer needs. (Merck & Co., Inc. is exhibiting in ICAAC booth 1426 and is conducting a satellite symposium on Saturday, 30 October at 7:00 AM entitled "Severe Bacterial and Fungal Infections: Clinical Strategies in the Setting of Antimicrobial Resistance and Compromised Immunity." Merck & Co., Inc. is the sponsor for the Abstracts on CD-ROM, Program Planner, and Registration Bags.)

**New Brunswick Scientific Company, Incorporated**  
44 Talmadge Road  
Edison, NJ 08818-4005  
www.nbsc.com

New Brunswick Scientific provides technology to the life sciences market, enabling the discovery, development, and production of pharmaceuticals

and other biologicals. This technology consists of hardware and the technical know-how, training, and support for our customers to convert their ideas into products. New Brunswick Scientific is committed to the design, development, manufacture, and support of the highest-quality equipment for life science research and pilot production.

**Olympus America, Incorporated**  
Two Corporate Center Drive  
Melville, NY 11747  
www.olympusamerica.com

A world leader in the development and application of sophisticated optical technology, Olympus has created innovative solutions for consumers, health care, and industry for over 80 years. From Japan's first microscope to the world's first Microcassette® recorder, from some of the most popular cameras in history to technology that tests 80% of the North American blood supply, the combination of innovative ideas, advanced technology, and manufacturing know-how has nourished their growth and satisfied customers worldwide since 1919.

**Quintiles Transnational**  
4709 Creekstone Drive  
Durham, NC 27703  
www.quintiles.com

Quintiles provides a full range of product development and commercialization services to the pharmaceutical and biotechnology industries. As the worldwide leader in clinical research, they have in-depth expertise in infectious diseases and an exceptional track record: more than 250 anti-infectives trials involving more than 315,000 patients in 49 countries. Worldwide, you can count on Quintiles to deliver the results you need. (Quintiles is exhibiting in ICAAC booth 1414.)

**Roche Laboratories, Incorporated**  
340 Kingsland Street  
Nutley, NJ 07110  
www.rocheusa.com

Roche is a leading health care company with a uniquely broad spectrum of innovative solutions. For more than 100 years, they have been active in the discovery, development, manufacture, and marketing of novel health care

solutions. Roche's products and services address prevention, diagnosis, and treatment of diseases, thus enhancing well-being and quality of life. Their focus is not just the diagnosis and treatment of manifest disease. The integrated health care approach is increasingly offering ways of identifying and targeting diseases early, when their damaging effects can still be prevented. Arranged in three operative divisions (pharmaceuticals, diagnostics, and vitamins and fine chemicals), Roche's global

mission today and tomorrow is to create exceptional added value in health care. (Roche Laboratories is exhibiting in ICAAC booth 1000 and is conducting two satellite symposia on Saturday, 30 October at 6:00 AM entitled "Building Blocks: Overcoming Obstacles of HIV/HCV Coinfection," and on Saturday, 30 October at 7:30 PM entitled "Herpes Viruses in the Highly Active Anti-Retroviral Therapy Era: a Changing Clinical Environment." Roche is the sponsor of the badge holders.)



**ASM**  
**BIODEFENSE**  
*Research Meeting*

2005

**ASM Biodefense Research Meeting**  
**March 20 – 23, 2005**  
**Baltimore Marriott Waterfront**

**ABSTRACT SUBMISSION DEADLINE:**

**January 24, 2005**

[www.asmbiodefense.org](http://www.asmbiodefense.org)

## ASM Report

### 2004 Election Nominees

#### National Offices

The Nominating Committee has submitted the following slate of candidates for the Society offices for the year 1 July 2005 through 30 June 2006. Members of the Nominating Committee were: Ronald Atlas (chair), Samuel Kaplan, Terry Beveridge, Barry Beatty, Joe Campos, Patricia Charache, and Ruth Berkelman. The Society will continue to offer the easier online balloting system with "streamlined access." All members will be expected to vote online. (Paper ballots will be mailed to members without an e-mail address on file.) The online voting system will open 1 October and close 10 December 2004.

#### President-Elect

**Diane Griffin**, John Hopkins School of Public Health, Baltimore, Md.

**Kathryn V. Holmes**, University of Colorado, Health Sciences Center, Denver

#### Secretary

**Judy A. Daly**, University of Utah, Salt Lake City



Daly

#### Treasurer

**Ronald B. Luftig**, Louisiana State University Medical Center, New Orleans



Luftig

#### Divisional Officers

Divisional nominating committees have selected candidates for group representatives, chair-elects, Division councilors at large, and alternate councilors to be voted on in the Fall 2004 elections (see p. 486-489).

#### Proposed Amendments to the ASM Bylaws

At the 2004 General Meeting, the ASM Council voted to adopt the following amendment to the ASM Bylaws concerning the process for election of officers in a new division.

In **Article VIII. Divisions, Section 3**, as amended shall now read:

**Section 3.** Upon creation of a Division, the person taking responsibility for the formation of the Division becomes the Chair (pro tem) until June 30 of the following year. The President, upon receipt of recommendations from the Chair (pro tem), shall appoint a Chair-Elect (pro tem) and a Councilor (pro tem). The Chair-Elect (pro tem) would not automatically assume the role of Chair at the end of the term. The Chair-Elect (pro tem) would stand for election as Chair on the very next ballot.\* The Councilor (pro tem) would serve a one-year term ending June 30 of the year following appointment.

The President shall also appoint a nominating committee to identify nominees to serve as candidates (Chair-Elect, Councilor, and Alternate Councilor) on the next ballot.\* Once elected officers are in position, a new chair-elect would be elected each year and an alternate councilor every two years. (\*The term "next ballot" refers to the ballot presented in the Fall of the same year the Division is approved by Council.) Vacancies occurring for any reason shall be filled by the President with advice from the General Meeting Program Committee and the elected officers of the Division. Thereafter, an election by ballot shall be conducted for the positions of Chair-Elect and Alternate Councilor in accordance with Section 4 which follows.

**Statement of Diane E. Griffin—ASM President-Elect candidate.** I am honored to be nominated as a candidate for ASM President. After many years of benefiting from the Society, I would be pleased to contribute time and effort by serving as president.

My interest in microbiology began in college in Illinois when I was first exposed to an excellent introductory course in microbiology. This interest was pursued in graduate school at Stanford University School of Medicine in the Department of Microbiol-

ogy headed by Sidney Raffel, a pioneer in the study of immune responses to infection. My thesis work with Leon Rosenberg was on antibody specificity. While at Stanford I became very interested in the diseases



Griffin

that microbes cause and enrolled in the M.D. program to earn a dual M.D.-Ph.D. degree. After completing two years of clinical training in Internal Medicine at Stanford, I moved to Johns Hopkins University School of Medicine for postdoctoral training in Infectious Diseases in the Department of Medicine and in Virology with Richard Johnson in the Department of Neurology. Here, as part of an exciting group of postdoctoral fellows from diverse scientific backgrounds, I learned virology and integrated approaches to the study of pathogenesis of viral infections. Studies on arbovirus encephalitis and measles were initiated during this time and remain areas of major interest in my laboratory.

My entire professional career has been at Johns Hopkins, first in the Departments of Medicine and Neurology in the School of Medicine, and more recently as chair of the Department of Molecular Microbiology and Immunology in the School of Public Health. My research interests remain in the areas of pathogenesis of viral infections, immune-mediated control of infection, and vaccine-induced protection from infection. The measles studies have involved research efforts and collaborations in Peru and Zambia. I have been actively involved in microbiology education through directing the microbiology course for medical students at Johns Hopkins and the virology course for graduate students and through microbiology test development with the National Board.

I have participated in a number of ASM activities, primarily in ASM-sponsored meetings and as an editor for the *Journal of Virology*. The ASM organization and staff are superb and effectively use the talents of the large number of volunteer microbiologists who serve on many ASM committees and participate in ASM meetings. ASM provides leadership in informing government organizations on policy

issues and is an effective advocate for microbiology research.

Microbiology is not only a fascinating field for research, but knowledge of microbes is increasingly important for public policy decisions. This is evident in the rapidly growing threats of antibiotic-resistant bacteria, emerging infectious diseases, and bioterrorism. Perhaps even more important is the increasingly expanded recognition of the usefulness of microbes as tools, vaccine platforms, environmental agents, evolutionary probes, etc. In the current climate, there will be many challenges to the field of microbiology related to oversight of experimental protocols, publication, laboratory security, and free exchange of information. The ASM will need to continue to play a leadership role in informing the public and in providing wise counsel to government agencies and investigators. I would be pleased to contribute to these efforts.

#### **Statement of Kathryn Holmes—ASM President-Elect candidate.**

I am honored to be a nominee for ASM President-Elect. ASM accomplishes a wide variety of important tasks for microbiology with the aid of a host of dedicated volunteers and talented professional staff members. I would like to help ASM to maintain its excellent programs and to encourage innovations that address new opportunities and problems that affect ASM members.



Holmes

My undergraduate work at Harvard included a senior honors research project on fungal genetics, and courses in virology and bacterial genetics and biochemistry. The new molecular genetics techniques that were then being developed presented exciting opportunities for discovery and clinical applications. As a graduate student in Purnell Choppin's lab at the Rockefeller University I became fascinated with the intimate, intricate interactions between viruses and their host cells. I also developed a lifelong interest in the pathogenesis of infectious diseases. My postdoctoral work with Keith Porter provided insight into the emerging field of molecular

cell biology. I have been a faculty member in Microbiology or Pathology Departments of four medical schools during a time when the practice of medicine and infectious diseases changed very rapidly as new diagnostic tests, vaccines, and drugs were developed and new infectious diseases of humans, animals and plants were discovered. I enjoy teaching microbiology to medical students and graduate students and giving seminars on our coronavirus research at scientific meetings. I also have enjoyed participating in the advancement of virology as a former president of the American Society for Virology, ASM Division Chair and Division IV Group Representative, and as chair of meetings on virology and microbial pathogenesis.

ASM continually addresses problems that affect our discipline. Current problems include how to improve ASM-sponsored meetings, maintain the high quality of ASM journals, and respond in a balanced way to new governmental initiatives on bioterrorism.

One of the principal goals of ASM is to provide accurate, up-to-date information about microbiology to many different groups, including microbiologists, physicians, students, legislators, journalists, and the lay public. These goals are accomplished in part through ASM sponsored meetings. Many changes have been made in the large annual ASM and ICAAC meetings to make them manageable for attendees, but new ideas to improve these big meetings would certainly be welcome. ASM also sponsors smaller meetings on special topics and ASM Branch meetings throughout the country. New ideas to improve Branch meetings would benefit many ASM members. I would encourage ASM participation in additional small meetings in bacteriology, virology, mycology, and infectious diseases.

The excellent work of the ASM editorial boards and publication staff has maintained the very high quality of the ASM journals through a period of rapid change associated with a transition to Web-based communications that challenges traditional publication purchasing by libraries and individuals. ASM will continue to be a leader in the ongoing discussions of how best to serve the need for well-refereed, rapidly published advances in microbiol-

ogy while supporting the publishing infrastructure.

Bioterrorism, emerging infectious diseases, antimicrobial resistance, and food and environmental safety have kept microbiology at the forefront of the news. Through the Public and Scientific Affairs Board (PSAB), ASM provides experts to testify at hearings, distributes accurate microbiology information to legislators, and formulates responses to queries about important issues such as biosafety and biosecurity. I believe that these are the most important issues facing us today and strongly support the role of ASM in public affairs.

We all recognize that outbreaks of infectious diseases in humans, animals, insects and plants can rapidly affect the entire globe, no longer just isolated regions. As a long-time coronavirus expert, I learned from the recent SARS pandemic about the need for international collaboration between microbiologists and policy makers in conquering emerging infectious diseases. This urgent need for united scientific initiatives comes at a time when fear of bioterrorism threatens to increase isolation of scientists from different countries. The flow of creative scientists from all over the world through microbiology labs and meetings in the United States, and the participation of U.S. microbiologists at meetings in other countries, lead to long-lasting relationships that support international scientific cooperation. The challenges to ASM are to continue to work creatively toward: 1) supporting international scientific exchanges including training of foreign students; 2) easing visa restrictions to allow foreign scientists to attend meetings and work in labs in the United States; 3) sponsoring microbiology lecturers in developing countries; and 4) exploring the relationships between free scientific exchange and biosecurity and biosafety in a changing world.

## **Education Board**

### **2004 Leadership Alliance Symposium**

The Education Board staff attended and participated in the annual Leadership Alliance Symposium, held at the Westfields

**Division Officers 2005 (terms begin 1 July 2005). Elections for Alternate Councilors are held on alternating years; asterisks indicate elections to be held in 2005.**

DIVISION	CHAIR	CHAIR-ELECT	ALTERNATE COUNCILOR
<b>A</b> Antimicrobial Chemotherapy	<b>Barry N. Kreiswirth</b> Public Health Research Institute Newark, NJ	<b>Karen Bush</b> J&J Pharmaceuticals Raritan, NJ	*
		<b>Joachim Trias</b> Vicuron Pharmaceuticals, Inc. Fremont, CA	
<b>B</b> Microbial Pathogenesis	<b>Joanne N. Engel</b> University of California San Francisco, CA	<b>Michael S. Donnenberg</b> University of Maryland/School of Medicine Baltimore, MD	<b>Brad Cookson</b> University of Washington Seattle, WA
		<b>Brenda A. Wilson</b> University of Illinois Urbana, IL	
<b>C</b> Clinical Microbiology	<b>David L. Tison</b> MultiCare Health Systems Tacoma, WA	<b>Diane Halstead</b> Baptist Medical Center Jacksonville, FL	*
		<b>Nancy Cornish</b> The Pathology Center Omaha, NE	
<b>D</b> General Medical Microbiology	<b>Ming Tan</b> University of California Irvine, CA	<b>Timothy Yahr, Ph.D.</b> University of Iowa Iowa City, IA	<b>Susan E. H. West</b> University of Wisconsin Madison, WI
		<b>Everett C. Pesci</b> East Carolina University Greenville, NC	
<b>E</b> Immunology	<b>Catherine C. Davis</b> The Procter & Gamble Co. Cincinnati, OH	<b>Stefan H.E. Kaufmann</b> Max-Planck-Institute for Infection Biology Berlin, Germany	*
		<b>Joseph Igietseme</b> Center for Disease Control Atlanta, GA	
<b>F</b> Medical Mycology	<b>Theodore C. White</b> Seattle Biomedical Research Institute Seattle, WA	<b>Arturo Casadevall</b> Albert Einstein University/College of Medicine Bronx, NY	<b>Brian Wong</b> Yale University New Haven, CT
		<b>Pete Magee</b> University of Minnesota Minneapolis, MN	<b>Christine Morrison</b> CDC Atlanta, GA
		<b>Errol Reiss</b> CDC Atlanta, GA	

*Continued*

**Divisional Officers, 2005**

<b>DIVISION</b>	<b>CHAIR</b>	<b>CHAIR-ELECT</b>	<b>ALTERNATE COUNCILOR</b>
<b>G</b> Mycoplasmology	<b>Daniel R. Brown</b> University of Florida Gainesville, FL	<b>Michael J. Calcutt</b> University of Missouri-Columbia Columbia, MO	<b>Barry Cole</b> University of Utah School of Medicine Salt Lake City, UT
		<b>R. Doug Hardy</b> The University of Texas Southwestern Medical Center Dallas, TX	<b>Jerry W. Simecka</b> University North Texas Health Science Center Ft. Worth, TX
<b>H</b> Genetics & Molecular Biology	<b>Tina M. Henkin</b> The Ohio State Univeristy Columbus, OH	<b>Anna C. Glasgow Karls</b> University of Georgia Athens, GA	<b>Craig Stephens</b> Santa Clara University Santa Clara, CA
		<b>Paul Babitzke</b> Penn State University University Park, PA	<b>Michele Igo</b> University of California Davis, CA
<b>I</b> General Microbiology	<b>Dennis Grogan</b> University of Cincinnati Cincinnati, OH	<b>Louis S. Tisa</b> University of New Hampshire Durham, NH	*
<b>J</b> Ultrastructure & Function	<b>David Popham</b> Virginia Tech Blacksburg, VA	<b>John Kirby</b> Georgia Institute of Technology Atlanta, GA	<b>Ken F. Jarrel</b> Queen's University Kingston, ON Canada
<b>K</b> Microbial Physiology & Metabolism	<b>William Metcalf</b> University of Illinois Urbana, IL	<b>John Foster</b> University of Southern Alabama Mobile, AL	*
		<b>Robert Kadner</b> University of Virginia Charlottesville, VA	
<b>L</b> Nosocomial Infections	<b>Neil Fishman</b> University of Pennsylvania Health System Philadelphia, PA	<b>David Henderson</b> NIH Clinical Center Bethesda, MD	<b>Louise-Marie Dembry</b> Yale New Haven Hospital New Haven, CT
<b>M</b> Bacteriophage	<b>Eric Miller</b> North Carolina State University Raleigh, NC	<b>Forest Rohwer</b> San Diego State University San Diego, CA	*
		<b>Sankar Jankar Adhya</b> NCI/NIH Bethesda, MD	
<b>N</b> Microbial Ecology	<b>Laura G. Leff</b> Kent State Kent, OH	<b>Marc E. Frischer</b> Skidaway Institute of Oceanography Savannah, GA	<b>Klaus Nusslein</b> University of Massachusetts Amherst, MA

*Continued*

**Division Officers 2005**

<b>DIVISION</b>	<b>CHAIR</b>	<b>CHAIR-ELECT</b>	<b>ALTERNATE COUNCILOR</b>
<b>O</b> Fermentation & Biotechnology	<b>Charles Abbas</b> Archer Daniels Midland Co. Decatur, IL	<b>Cheryl A. Nickerson</b> Tulane University School of Medicine  New Orleans, LA	*
		<b>Hans Blaschek</b> University of Illinois Urbana, IL	
<b>P</b> Food Microbiology	<b>Stephen J. Knabel</b> The Pennsylvania State University University Park, PA	<b>Martin Wiedmann</b> Cornell University Ithaca, NY	<b>Timothy Freier</b> Cargill Minneapolis, MN
		<b>Andrew Benson</b> University of Nebraska Lincoln, NE	<b>Amy C. Lee Wong</b> Food Research Institute Madison, WI
<b>Q</b> Environmental & General Applied Microbiology	<b>Hilary M. Lappin-Scott</b> University of Exeter Exeter, UK	<b>James Maki</b> Marquette University Milwaukee, WI	*
<b>R</b> Evolutionary & Genomic Microbiology	<b>Jeffrey Lawrence</b> University of Pittsburgh Pittsburgh, PA	<b>Anthony Michael Dean</b> University of Minnesota St. Paul, MN	<b>Martin G. Klotz</b> University of Louisville Louisville, KY
<b>S</b> DNA Viruses	<b>Mary Kathleen Rundell</b> Northwestern University Chicago, IL	<b>Jim Alwine</b> University of Pennsylvania Philadelphia, PA	*
		<b>Theresa Compton</b> University of Wisconsin Madison, WI	
<b>T</b> RNA Viruses	<b>Peter W. Mason</b> University of Texas Medical Branch Galveston, TX	<b>Cornelia Bergmann</b> USC Keck School of Medicine Los Angeles, CA	*
<b>U</b> Mycobacteriology	<b>Robert S. Wallis</b> University of Medicine and Dentistry of New Jersey Newark, NJ	<b>Issar Smith</b> International Center for Public Health Newark, NJ	*
		<b>Rich Frothingham</b> Duke University Medical Center Durham, NC	
<b>V</b> Clinical & Diagnostic Immunology	<b>Steve Callister</b> Gundersen Lutheran Medical Center La Crosse, WI	<b>Brian K. DuChateau</b> The Blood Center of Southeastern Wisconsin Milwaukee, WI	<b>John Schmitz</b> UNC Hospitals Chapel Hill, NC
<b>W</b> Microbiology Education	<b>Marion F. Fass</b> Beloit College Beloit, WI	<b>Jeffrey C. Pomerville</b> Glendale Community College Glendale, AZ	*
		<b>Marjorie (Kelly) Cowan</b> Miami University of Ohio Cincinnati, OH	

*Continued*

**Division Officers 2005**

DIVISION	CHAIR	CHAIR-ELECT	ALTERNATE COUNCILOR
<b>X</b> Molecular, Cellular & General Biology of Eukaryotes	<b>Jac A. Nickoloff</b> University of New Mexico School of Medicine Albuquerque, NM	<b>John M. Logsdon, Jr.</b> University of Iowa Iowa City, IA	<b>Rebecca S. Hartley</b> University of New Mexico Albuquerque, NM
<b>Y</b> Public Health	<b>Lisa Jackson</b> Group Health Hospital Seattle, WA	<b>Ralph J Timperi</b> MA State Laboratory Institute Boston, MA	<b>Brian D. Sauders</b> Cornell University Cortland, NY
<b>Z</b> Animal Health	<b>Thad B. Stanton</b> National Animal Disease Center Ames, IA	<b>Thomas Besser</b> Washington State University Pullman, WA	*
<b>AA</b> Free-Living, Symbiotic, and Parasitic Protists	<b>Louis Weiss</b> Albert Einstein College of Medicine New York, NY	<b>Kasturi Haldar</b> Northwestern University Chicago, IL	*

**Group Representative Candidates**

**Divisional Group I—**

Diagnostic Microbiology and Epidemiology  
Divisions: C, F, L, U, and Y

**Carolyn M. Black** (re-election)  
Centers For Disease Control  
Atlanta, GA

**Divisional Group IV—**

Molecular Microbiology, Physiology, and Virology  
Divisions: H, J, K, M, S, T, X, and AA

**Linda J. Kenney** (re-election)  
University of Illinois  
Chicago, IL

**Division Councilors at Large**

**Caroline R. Genco** (re-election)  
Boston University School of Medicine  
Boston, MA,

**Robert A. Weisberg** (re-election)  
NIH  
Bethesda, MD

**Christon J. Hurst**  
U.S. Environmental Protection Agency  
Cincinnati, OH

Marriott Conference Center in Chantilly, Va., on 30 July–1 August 2004. The Leadership Alliance is a consortium of 31 leading research and teaching academic institutions, dedicated to improving the participation of underserved and under-represented students in graduate studies and Ph.D. programs and, ultimately, research professions in the academic, public, and private sectors.

The symposium is made up of student oral and poster presentations, workshops, panel discussions, and an exhibit program. The theme of this year's symposium was "Taking the Next Step." Two hundred

and eighty-eight undergraduate students and thirty-eight graduate students participated in the program. Nicole Easley, a 2004 ASM Minority Undergraduate Research Fellow (MURF), attended and presented a poster titled "Establishing the Role of SytB and SytE as Virulence Factors in Geminiviruses using the Plant Model *Arabidopsis Thaliana*" at the conference. Also in attendance were past Minority Undergraduate Research Fellows Terry-Ann Smith (2002 awardee), Marcus B. Jones (1999 awardee), Joeli Marrero (1999 awardee), and Geanncarlo Lugo-Vallarino (1997 awardee).

Information about the Leadership Alliance can be found at the website <http://www.theleadershipalliance.org>.

**Membership**

**Awards**

**Hiroshi Nikaido** will receive the 14th Annual Bristol-Myers Squibb Freedom to Discover Award for Distinguished Achievement in In-



Nikaido

fectious Diseases Research for his pioneering work on bacteria, their transport systems, and their role in both antibiotic action and resistance. Nikaido is professor of biochemistry and molecular biology at the University of California, Berkeley. Nikaido's work has contributed greatly to understanding of solute transport across the bacterial cell wall. His studies on porin proteins revealed the physico-chemical limitations of uptake of antibacterials, especially  $\beta$ -lactams, in the cell. In the 1990s Nikaido spearheaded fundamental studies of efflux of antibacterial agents. His studies have been complemented by robust mathematical models which have led to an understanding of the role of uptake and efflux not only in inherent drug resistance in major pathogens, but also in bacterial multiple drug resistance. Nikaido's efforts have resulted in critically important clinical applications. The Bristol-Myers Squibb 'Freedom to Discover' Unrestricted Biomedical Research Grants and Awards Program, under which the Distinguished Achievement Award is presented, was initiated in 1977. On its 25th anniversary in 2002 it reached a \$100-million milestone in funding in six biomedical research areas: cancer, cardiovascular, infectious disease, metabolic disease, neuroscience, and nutrition. The Distinguished Achievement Award is presented annually in each of the six categories. The award, a \$50,000 cash prize and a silver commemorative medallion, will be officially presented at the annual Bristol-Myers Squibb Distinguished

Achievement Award Dinner to be held in New York City on 14 October 2004.

### Deceased Member

**Jean Ruth Adams, 75**, a longtime insect pathologist with the U.S. Department of Agriculture, died of cancer on 12 July at her home in Hyattsville, Md. Adams received her bachelor's degree in Agricultural Research in 1950 and her Ph.D. in Entomology in 1962 from Rutgers University, New Brunswick, N.J. Between degrees, she spent 5 years as a laboratory technician at Rohm and Haas, where she helped to develop and test the miticide Karathane. She joined the Insect Pathology Laboratory at the Beltsville Agricultural Research Center in 1962 after post-doctoral training at the University of Pennsylvania. Her long, distinguished career with the USDA included over 70 publications and the discovery of numerous insect pathogens. As the premier electron microscopist working in insect pathology, she was regularly sought by collaborators from around the world for help in identifying the cause of insect deaths. Electron microscopy was a new technique at the start of her career and required significant modifications of the preservation techniques before one could obtain usable images.



Adams

Ultimately, she succeeded in obtaining excellent electron micrographs of many insect pathogens. Of particular note was some early research that showed the presence of two distinct morphological forms (singly and multiply embedded) of insect viruses in the *Nucleopolyhedrovirus* genus. Also noteworthy was the publication of the *Atlas of Invertebrate Viruses*, which she edited with J. R. Bonami near the end of her tenure with the USDA. Even after her official retirement from the USDA in 1996, she continued as an active collaborator in the Insect Biocontrol Laboratory, helping to catalog the many specimens of insect viruses obtained through her research career. Adams was an active member of many professional societies, including the Society for Invertebrate Pathology (Secretary, 1982–84), the Electron Microscopy Society of America (Local Arrangements Committee, 1981–82; Scientific Exhibits chair, 1982), the Chesapeake Society for Electron Microscopy (Council member, 1976–78; Secretary/Treasurer, 1976–78; Secretary, 1980–82), the Entomological Society of America, the Maryland Entomological Society, the Washington Entomological Society, ASM, and several others.

Adams never married. Survivors include a brother, Robert Adams of New Egypt, N.J.; and sister, G. Anne Carter of Rancho Palos Verdes, Calif.; six nieces; one nephew; eight grandnieces, and six grandnephews. Her mother, Gertrude, died in 1962, and her father, Raymond, died earlier this year.